MCQ 25492551

PQ 191 Rx CU 65 et al.

1.

2.

3.

4.

**

MCQ
( MCQ OSPE) **
MCQ 2549 case 2
10 case 2 20 case case 15 300 (
)
MCQ 2549 case 2
15 case 2 30 case case 10 300
()
4 A,B,C,D
()

1
(
)

case

: :
4:3:3 ( 2551)
(
)

..
-

- , , ,
(), (), (), , ,
New Light
(), (USA)
5
-


2549 (
1)
1



:

1.

a. ( tuberculosis)
b. (pneumonia)
c. (gonorrhoea)
d.

7.
4

1. zidovudine 100 mg 2.
ritonavir 3. azithromycin tab
150 mg 4. rifampicin

1. zidovudine

(candidosis)
e. ( HIV)

2.
3. GPOvir

3.azithromycin

a. Zidovudine +
Didanosine + Ritronavir
b. Stavudine + Lamivudine
+ Saquinavir
c. Stavudine +
Lamivudine
+Nevirapine

4. rifampicin
2.
ritonavir
8.

zidovudine
5. a. Inhibit protein synthesis
Inhibit HIV protease

c. Inhibit HIV reverse

transcriptase
lipodystrophy d. Inhibit thymidine kinase

e. Inhibit cell wall synthesis

a. Abacavir
9. Ritronavir
b. Ritonavir

c. Nevirapine
a.
d. Lamivudine

e. Diravirdine
b.
6.
....

peptide-like
a. Cotrimazole
...
b. Nystatin
d. basic functionality
c. Claritromycin
ionize
4.

e.

polar functionality

10. Rifampin
white sugar-coated
tablet

a. air

oxidation
b.
hydrolysis
hydrozone
c.

d.

e.

2
24

11.

a. Bacterial vaginosis
b. Candidiasis
c. Gonorrhea
d. Herpes genitalis
e. Trichomoniasis
12.

a. Tinidazole
single dose
b. Metronidazole
single

dose
c. Clotrimazole
7

d. Ciprofloxacin

e. Cotrimoxazole

13.

a. Tetracyclin
250 mg
b.
3
c.

d.

e.

14.

a.
b.

c. 8
15 c
d.

e.
2g
15.

a.
b.
c.
d.
e.

Natural fat base

Synthetic fat base
Water soluble base
Emulsion base
Absorption base

16.

a. Clotrimazole
b. Cotrimoxazole
c. Itraconazole
d. Metronidazole

17.
18.

a.
b.
c.
d.

e.
19.

a. Case control
b. Randomized control
study
c. Case
d. Analysis of secular trend
20.

Vanotab

a
2x2pc 20
70%
1

1 OD 1
?
90%
Vanota

a. 90
b. 98
c. 100
d. 103
e. 110
3
32
Partial

seizure secondarily to
generalized tonic-clonic seizure
Phenytoin
sodium (100mg) 3 capsule hs

1

Phenytoin
28
mg/L (
Phenytoin
10-20 mg/L)
21.

a.

b.

c.

d.

..
e.

2
22.
Phenytoin

Sodium
a. Ethosuximide
b. Diazepam
c. Vigabutrin
d. Carbamazepine
e. Gabapentin
23.
Phenytoin

a. Glugival hyperplasia
b. Hepatitis
c. Rash
d. Ataxia
e. Hyponatremia

24.

a. Phenytoin
b. Valproate

c. Phenobarbital

d. Carbamazepine
25.
phenytoin phenytoin

a. Erythromycin
b. Cimetidine
c. Conjugated estrogen
26. phenytoin

a.
b.
c.
d.

Lactose
Dextrose
Calcium sulfate
Pregelatinized starch
e. Microcrystalline cellulose
27.
phenytoin

a. Crospovidone
b. Croscarmellose
c. Sodium lauryl
sulphate
d. Sodium starch glycolate
e. Colloidal silicone dioxide

28.

29. phenytoin

a. infrared
spectroscopy (IR)
Benzene
b. infrared
spectroscopy (IR)
secondary amide
c. infrared
spectroscopy (IR)
carbonyl
d. ultraviolet
spectrometry (UV)
Benzene

e. ultraviolet

spectrometry (UV)
secondary amide
30.

......2540
Phenytoin

a.

b.
c.
d.

e.
4
50
Non-Small Cell Lung Cancer
(NSCLC) Satge IV

Cisplatin 100 mg/m2 IV drop

over 1 hour on day 1
Etoposide 100 mg/m2 IV drip
over 1 hour on day 1,2
60 kg. 180
cm Surface area= 1.73 m2

31. Cisplatin

a. 150
b. 175
c. 200
d. 225
e. 250
32.
Acute Emetic

a. Ondansetron
b. Dexamethasone
c. Metoclopramide
d. Ondansetron +
Dexamethasone

e. Metoclopramide +
Dexamethasone
33. Cisplatin

a.
b.
c.
d.
e.

a. Akylating agent
b. Topoisomerase II
inhibitor
c. Antimetabolite
d. Intercalating agent
e. Inhibitor of mitosis
34. Cisplatin
(Nephrotoxicity)

a.

b.
Magnesium
c. Osmotic
diuretic Mannitol
d. Cisplatin
Sodium chloride
35. etoposide
stability

: At temperature in D5W or NS
in polyvinyl
0.2 mg/ml
: 96
hours
0.4 - 0.21 mg/ml
:
48 hours
0.6 - 0.41 mg/ml
: 8
hours
1.0 - 0.61 mg/ml
: 2
hours
manufacturer does not
recommended administration at
conc. more than 0.4 mg/ml due
to highly unpredictable time to
precipitation
etoposide

(100 mg/m2) D5W 500
ml

96 .
48 .
8 .
2 .

36.

a.

b.

.....
c.

d.

e. ()

37.
Cisplatin

a. Doxorubicin
b. Cytarabine
c. Melphalan
d. Carboplatin
e. Metrotrexate

38.

+
+
+ + + +
+ +
+- +- ++- +
+- -+
+ +

a. Diffusion controlled
b. Dissolution controlled
c. Erosion controlled

d. Osmotic controlled
e. Ion exchange
controlled

FBS (<126)
HbA1c (<7)

39.
2

A
c

135 mg%
7.0%

Myocardial infarction
53
44
Glibencarmide 10 mg

BID
41. LDL- C
B

a. A hydrophobic

medium
b. B hydrophilic
medium
c. C hydrophobic
medium
d. B

e. C

40.

a. Clean room class

100,000
b. Clean room class 10,000
c. Clean room class 1,000
d. Horizontal laminar
airflow hood
e. Biological safety
cabinet
5 53
5
3-4

BP 138/88 mmHg HR 85 RR
18/min

Total cholesterol (<240) 243

mg/dL
Triglyceride (<200) 200
mg/dL
HDL- C (>40)
33mg/dL

a. 130 mg/dl
b. 140 mg/dl
c. 150 mg/dl
d. 160 mg/dl
e. 170 mg/dl
42. major risk factor
Coronary heart
disease
Myocardial
infarction 53
Myocardial
infarction 44
2
HDL-C 33 mg/dl
53
43.
Hyperlipidemia
a. Total cholesterol
b. Triglyceride
c. HDL-C
d. LDL-C
e. Non-HDL-C
44.
LDL C
atherosclerosis
a. < 100 mg/dl
b. < 130 mg/dl
c. < 160 mg/dl
d. < 190 mg/dl

e. < 200 mg/dl

45.

a. Statin
b. bile acid

segvegtrants
c. nicotinic acid

d. fibric acid
e. plant sterols

sitosterol campesterol
46. Statin
LDL-C
a. LDL-C
receptor
b. cholesterol
LDL-C
receptor
c. enterohepatic
recycling cholesterol
d. VLDL
e. HDL

a. Pravastatin

prodrug
b. Simvastatin
Pravastatin prodrug
c. Pravastatin
2

lactone ring
carboxylic acid
d. Simvastatin

lactone ring
e. Simvastatin
Pravastatin

prodrug

Simvastatin
Pravastatin
47.

a. Cholestyramine
Simvastatin
Simvastatin lactone
ring
b. Cholestyramine
Pravastatin
Pravastatin
carboxylic acid

c. Simvastatin
Cholestyramine
d. Cholestyramine

Simvastatin

Provastatin
e. Cholestyramine
Simvastatin
Provastatin
48.

49.

Drug use
statin

a.
b.

c.

d. ...

e.

50.
statin
....

a. Cohort study , Case

controlled study
b. Case report, Crosssectional study
c. Case controlled study,
Cross-sectional study

d. Meta-analysis,
Randomized
controlled study
e. Cross-sectional study,
Randomized controlled
study
6 25
10

a.
b.

c.
d.
e.

Salbutamol MDI

51.

a.

b.

c.

d.

e.

52.

53.

Salbutamol MDI
a. long-

acting beta 2 antagonist

b. inhaled
steroid steroid
c.

d. attack 2-4
puffs
3

e.

bioavailability
54. 2

a. Inhaled fenoterol
(100mcg/puff) 3
puffs
b.Zileuton (600mg/tablet)
1 4
c. Sustained-released

theophylline (200mg)
1 2
d.Inhaled budesonide (200
mcg/puff) 2 puffs
2
e. Ketotifen (1mg/tablet)
1 2
55.

a. Inhaled Salmeterol DPI

(50 mcg/blister)
1 blister 12 .
b.Inhaled Cromolyn MDI
(1mg/puff) 2 puff
3
c. Inhaled Fluticasone DPI
(250 mcg/inhalation)
2 inhalation 3
d.Prednisolone (5 mg/tab)
5

e. Inhaled Ipratopium MDI (18

mcg/puff) 2 puff
3
56.
steroid

a. Sore throat
b. Pharyngitis

c. Metallic taste

d. Gingivitis
e. Oral thrush
57.

Theophylline
a. Ciprofloxacin
b. Fluvexamine
c. Cimetidine
d. Amoxicillin
e. Rifampicin
58.

inhaler device

a. spacer

Metered Dose Inhaler

(MDI)

oral thrash

b.

Nebulizer
c. Dry powder
Inhaler (DPI) ...

10

d. breath
activated device

e. Turbuhaler

59.

a. Turbutaline (2.5mg/tab)
b. Prednisolone
(5mg/tab)

c. Inhaled fermoterol (4.5

mcg/dose)
d. Inhaled beclomethasone
(250 mcg/puff)
e. Theophylline (200 mg
sustained-release)
60. Evohaler
a. metered dose
inhaler
b. propellant

c. propellant nonCFC

d.

e.

7 33

61.

a. Prednisolone

b. Hydrocortisone,
cimetidine
c. Hyossacine HCl, Zinc
oxide
62.

a. Senna
b. Castor oil
c. Bisacodyl
d. Mineral oil
e. Phylium seed
63.

a.
6
b.

c.

d. 1

e.

64.

a.
b.
c.

d.

e.

65.

a. Senna
b. Castor oil
c. Bisacodyl
d. Lactulose
e. Phylium seed

66.

a.
b.

c.

d.

e.
15
67.

2g
0.3g Displacement
valve = 1.5
base

a. 155 g
b. 175 g

c. 180 g
d. 197 g
e. 200 g
68.

15

a. Calcium carbonate
b. Potassium chloride
c. Sodium bicarbonate
d. Potassium lichromate
e. Potassium
permanganate
69.

.....
15 3

a.

b.

c.

d.

e.

70.

a.

b.

c.

d.

e.

8
60 48 kg 170
cm

Blood urea nitrogen = 60

mg/dl (normal 7-20 mg/dl)
Serum creatinine
concentration = 3 mg/dl (normal
0.5-1.4 mg/dl)
Serum potassium
concentration = 6.5 mEq/l (normal
3.5-5.2 mEq/l)

creatinine
clearance 18 ml/min
71.

Creatinine clearance

a.
b.
c.
d.
e.

Acute renal failure

Renal insufficiency
Chronic renal failure
Uremia
End-state renal failure

72.
hyperkalemia

a. Potassium chloride

b. Sodium chloride
c. Sodium polystyrene
sulfonate
d. Calcium chloride
e. Calcium phosphate
73.

a.
b.
c.
d.
e.

Hydrochlorothiazide
Spironolactone
Furosemide
Amiloride
Indapamide

74.

a.
b. renal shut down
c.

d. -

e.

acidosis
sodium bicarbonate
bicarbonate 2.8 mmol/l
sterile water for injection 100 ml
75.

sodium bicarbonate
sodium
bicarbonate
5 ml 2 mg/ml
(Mw Na=23, H=1, C=12,

O=16)
a. 2 Amp
b. 3 Amp
c. 4 Amp
d. 5 Amp
e. 6 Amp
76.

a. Clean room class 10

b. Clean room class 100

c. Clean room class 1000

d. Clean room class
10,000
e. Clean room class
100,000
77.

a.
b.
c.
d.

Sterility
Osmolarity
Microbial limit test
Particulate matter
e. Preservative

78.

Sodium bicarbonate injection

a.

b.

50,000
c.

d.

50,000
e.

79. A
diuretic
.......

HCTZ

A
a. Case control
b. Cohort
c. Meta-analysis of case
control studies
d. Deseriptive
e. Randomized control
trial

80.

a.
b.
c.
d.
e.
9
generalized
anxiety disorder

6
81.

a. Lithium carvonate
b. Clozapine
c. Chlorpromazine
d. Haloperidol
e. Diazepam
82.

fluoxetine
a.

b.

c.

d.
....

e.

83.


major depressive disorder

a. Venlafaxine

b.
c.
d.
e.

Paroxetine
Amitriptyline
Bupropion
Sertraline

84.

a. Imipramine
b. Elomipramine
c. Amitriptyline
d. Doxepin
e. Sertraline
85.
antidepressant

a.

b.

2-3

c.

d.

e.

86.
benzodiazepine

a.

b. Triazolam

25%

c. Olanzapine

75%

d.
25%

e.
1

87.

a.
b.
c.
d.
e.
88. Risperidone

methanol
HCl 0.1 normal

a. Shellac
b. Cellulose acetate
phthalate
c. Hydroxypropyl
methylcellulose
d. Polyvinyl acetate
phthalate
e. Polyvinyl pyrroridone
89.

a.

matrix

b.

osmotic

c.

d.

matrix
90.
( bulking
agent)
( disintegrant )

a. Lactose
b. Magnesium sulfate
c. Microcrystalline cellulose
d. Corn starch
e. Sodium lauryl sulfate
10 28

Thyroid stimulating hormone

(TSH)
Thyroxine

91.

a. Goiter, constipation,
lethargy, dry skin
b. Goiter, depression, puffy
face, lethargy
c. Goiter, cold intolerance,
decreased sweating,
bradycardia
d. Goiter, loose bowels,
insomnia, irritability
e. Goiter, fatigue, weight
gain, decreased appetite

Propanolol 20 mg QID for 3

weeks
Propylthiouracil 100 mg TID
for 6 weeks

cuthyroidal

state
92. Propylthiouracil

2542

a.

b.

c.

d.

e.

drug use evaluation

93.

a.
Propylthiouracil
methimazole

b.

Propylthiouracil

c.

d.
iodine
e. propranolol

propylthiouracil

94.
thiouracil
a.
b.
c.

d. SLE like syndrome

e. Metallic taste

dealkylation
Propyl group

95.

Propylthiouracil
a.

thiourea

b.

thyroid hormone
c. hypothyroid
d. thyroid
peroxidase
e. T3
96. Propylthiouracil: White,
crystalline sub that has a
bit ?? water
... 50 mg
3

methimazole

carbimazole

propyl
thiouracil

methimazole, carbimazole
propylthiouracil
a. methimazole,
carbimazole
propylthiouracil
metabolized
desulfunation

b. propylthiouracil
metabolized

c. methimazole
metabolized
conjagation
carbimazole

d. amide
hydrolysis
carbimazole

e. ester
hydrolysis
carbimazole

97.
propanolol

propylthiouracil
a. Propanolol alphaadrenergic blocking
agent
b. Propanolol
tremor
tarchycardia
thyrotoxicosis
c. Propanolol
pharmacokinetic
propylthiouracil

propylthiouracil
d. Propanolol

propylthiouracil
e. Propanolol
propylthiouracil
T4
98. goiter
a. Ion
thiocyanate
goiter

b. Thiocyanate
metabolize ...

c. Lithium
secretion Thyroxine
thiiodothyroxine

hyperthyroidism
d. Goitrin
thyroid peroxidase
e. Percholate ion
uptake
iodide
iodide thyroid
99. toxic goiter

a. iodine
b. iodine
c.

d.

e.
thiocyanide
100.
Lugols solution

a. Iodine + KI
b. Manganese
c. Methimazole
d. Thiocyanate
e. Propylthiouracil
11 55

estradiol

valerate 2 mg + norgestrel 0.5 mg

101.

a.

b.

c.

d.

e.

102.

(transdermal patch)

a.
first pass
metabolism
b.

c.

d.

e.
osteoperosis

103.

a. estradiol valerate 2 mg

+ norgestrel 0.5 mg
b. medroxyprogesterone
acetate 5 mg
c. ethimylestradiol 30 mcg
+ cypoterone acetate 2
mg
d. conjugated estrogen
0.625 mg
e. conjugated estrogen
0.625 mg +
medroxyprogesterone 5
mg
104.

103

a. Hyperlipidemia
b. Osteoperosis

c. Hyperbilirubinemia
d. Congestive heart failure
e. Thromboembolism
105.

Transdermal

a.
b.

c.

d.
partition coefficient
1
e.
therapeutic index
106.

a.
b.
c.
d.
e.
107.
spectrum
phytoestrogen

a. UV-visible
spectrophotometer
b. 1H-NMR spectrometer
c. 13C-NMR spectrometer
d. FT-IR spectro
e. Mass spectrometer
108.

a. B1-6-12 tablet
b. Doxycyclin capsule
c. Senna tablet
d. Antacid gel
e. Premarin 0.625 mg

109.

a.
b.
c.
d.
e.

Ibuprofen 400 mg
Dexamethasone 0.5 mg
Indomethazin 25 mg
Piroxicam 10 mg
Celebrex 200 mg

110.

a. Diazepam 10 mg

b.
c.
d.
e.

Diclofenac inj 75 mg
Methadone tab 10 mg
Pentazocine tab 25 mg
Voltaren SR tab 100 mg
12 22

Systemic Lupus
Erythematosus (SLE)

111.

SLE

a.
hydrazine
Lupus

b. sunscreen SPF
15
c.

d.
hydralazine
chorpropamide
anticonvulsant

lupus
e.

112.

topical steroid
topical steroid

a. Hydrocarbon base
b. Oleaginous base
c. Absorption base
d. O/W emulsion base
e. W/O emulsion base
Topical steroid

113.

a. Psuedoplastic flow
b. Psuedoplastic flow with
thixotropy
c. Dilantant flow with
thixotropy
d. Antithixotropy
e. Newtonium flow

SLE
hydroxychloroquin 200 mg
114.

a. Ocular examination
b. Chest x-ray
c. Liver function test
d. Urinalysis
e. EKG

aspirin
115.

aspirin tab

aspirin

Product A
Product B
Product C
Aspirin tab

a. Product A
b. Product B
c. Product C
d.

e.

116.

(rate constant, K)
aspirin tab

a. (slope)
b.
(slope)
c. Intercept
d. Intercept

e. Intercept
slope
117.

aspirin tab
a. (half life)
aspirin
b. (shelf life)
aspirin
c. .
aspirin
d. .
aspirin

e.
aspirin first order

rxn
118.

steroid
cytotoxic drug


TB

Isoniazid, Rifampin,
Pyrazinamide, Ethambutol
SLE

a.
b.
c.
d.

Isoniazid
Rifampin
Pyrazinamide
Ethambutol
e. Pyrazinamide
Ethambutol

Prednisolone
Dexamethasone

a. Dexamethasone

steroid short
acting steroid
b. Dexamethasone

steroid long
acting steroid
c. equivalent
dose

Potency
d.
Prednisolone
glucocorticoid
dexamethasone

predni
solone
a.
Pregnane
b. Amcinonide

antiinflamatory activity
prednisolone
c. Amcinonide
lipophilicity
prednisolone
d. Amcinonide salt
water retention
prednisolone
e. Amcinonide
9-F 11-OH
amcinonide
glucocorticoid activity
prednisolone

119.

mineralocorticoid
e.

13
45
1

paracetamol

121.

a. Rheumatoid arthritis
b. Osteoarthritis
c. Osteoporosis
d. Acute gout
e. Osteomalacia

120.
amcinonide
prednisolone

122.
amcinonide

a.
b.
c.
d.
e.

Paracetamol
Probenacid
Colchicine
Tramadol
Allopurinol

123.

a.
b.
c.
d.
e.
124.

a.
b.
c.
d.
e.

Prednisolone
Indomethacin
Allopurinol
Paracetamol
Tramadol

125.

a. Corticosteroid
b. Xanthine oxidase
inhibitor
c. Uricosuric agent
d. NSAID
e. Para-aminophenol
derivatives

126.

Rx

Diclofenac 25 mg # 30
Sig: 2 tab p.o. tid pc

% labeled amount
60
. ..

2510
a.
b.
c.
d.
e.
127.

a. Uncoated tablet
b. Enteric coated tablet
c. Efervessant tablet
d. Filmed coated tablet

e. Sugar coated tablet

128.

(enteric coated
tab)
a.

b.

c.

d.

e.

129.

a. Celecoxib
b. Tramadol
c. Meloxicam
d. Prednisolone
e. Indomethacine
130.

a.

b.

c.

d.
2

e.
3

14 19

131.

a. Staphylococcus
aureus

b. Staphylococcus
epidermidis
c. Streptococcus
pnuemoniae
d. Neisseria gonorrheae
e. Chlamydia tracamatis
132.

a. Dexamethazone eye
drop
b. Oxymethazoline eye
drop
c. Idoxuridine eye drop

133.

a. DNA

b.

c. RNA

d.

leucocytes
e. cell wall
134.

...
a. 25c 6-8

week
b. 25c 3-4

week
c. 2-8c 6-8

week
d. 2-8c 3-

4 week
e. 8-15c 3-

4 week
135.

C-3 hemisuccinoyl
ester

ester

C-3 hemisuccinoyl ester

a.

b.

c.

d.

e.

136.

2% A
180 ml isotonicity

(Freezing point
= -0.52 o c, freezing
point A 1% = -0.12 o c,
freezing point =

-0.58 o c)
a. 0.28%
b. 0.38%
c. 0.48%
d. 0.58%
e. 0.68%
137.
A

hydrolysis

A
a. complexing agent
b. pH pKa
c.

d. cosolvent
e.

lyophilized powder
A

138.

a. clay
b.

polysaccharide
c. cellulose
d. hydrated
silicate
e. colloidal
silicone dioxide

d. Topical steroid
e. Ketoconazole
shampoo
143.

topical steroids

topical
steroids

a. 0.1% betamethasone
valerate < 0.05%
betamethasone
dipropionate < 0.05%
clobetasone
propionate
b. 0.05% clobetasone
propionate < 0.1%
betamethasone valerate
< 0.05% betamethasone
dipropionate
c. 0.05% betamethasone
dipropionate < 0.05%
clobetasone propionate
< 0.1% betamethasone
valerate
d. 0.1% betamethasone
valerate < 0.1%
triamcinolone acetonide
< 0.05% clobetasone
propionate
e. 0.05% clobetasone
propionate < 0.1%
betamethasone valerate
< 0.1% triamcinolone
acetonide

139.

140.

polymycin B sulfate 10,000

units/ml 12
.. 2548

8,500 units/ml

a.
b.
c.
d.
e.
15 25

(greasy scale)
nasolabial folds
10

psoriasis
141.

a. Contact dermatitis
b. Psoriasis
c. Saborrheic dermatitis
d. Dandruff
e. Tinea vesicolor
142.

a. Selenium sulfide
shampoo
b. Tar shampoo
c. Salicylic acid

144.

a. Ketoconazole shampoo

12
b. Dandruff
Topical

corticosteroid

c. Sulfur

keratolytic agent
d. coal tar
photosensitivity
e. Selenium sulfide
hyperproliferation
cell
145.
ointment each g
contains: Betamethasone 0.5
mg and salicylic acid 30 mg
in a paraben freez ointment
base of white petroleum and
mineral oil
ointment base

a. water soluble ointment

base
b. oleaginous ointment
base
c. emulsion ointment base
d. absorption ointment
base
e. acidic ointment base

146.

salicylic acid
a.

b.

phospholipase

A2
c.
Keratolytic

agent
d.

antioxidant

e.

emulsifying agent
147.

Ketoconazole

a. Gas chromatography
b. UV/visible
spectrophotometer
c. IR spectroscopy
d. High performance
liquid
chromatography
e. High performance thin
layer chromatography
148.

Reg. no. 2C802/45

a.

..2545
b.
8 .. 2545
c.
8 ..

2545
d.

..2545
e.

8 .. 2545
149.

(Reg. no. 2C802/45)

a. 1
b. 2
c. 3
d. 4
e. 5
150.

a. Coal tar shampoo

b. Dexamethasone cream
c. Betamethasone +
salicylic ointment

d. Hydroxyzine tablet 25
mg
e. Methotrexate tab 2.5
mg

2549
( 2)
1 44

penicillin
1.

. Norfloxacin
. Ciprofloxacin
. Erytromycin
. Chloramphenical
. Amoxycillin
2.

10
penicillin
( anaphylaxis )
. Erytromycin
. Levofloxacin
. Azithromycin
. Chloramphenical
. Amoxycillin
3.

. Tetracyclin

. Dicloxacillin
. Erytromycin
. Cotrimazole
. Amoxycillin
4.
griseofulvin

5.

( randomized cross)

( randomized parallel)

.
( cohort study design)

.
( single binded design )

6.


5
. .. 2510
.
.
.
.
.

7.
flocculation

8.

sedimentation ratio
0.60
. sedimentation ratio

. sedimentation ratio

. sedimentation
ratio
9. Cloxacillin
sodium for oral solution
sig. 1 tsp. qid ac & hs

.
( ready to use)
.

. 1
4
.

.
2
12
3

11.




Aspirin

. folic acid
. vitamin B 12
. ferrous gluconate
.

. ferrous sulfate
folic acid
12.
.
G6PD
. aplastic anemia
. hemolytic anemia
. pernicious anemia
. chronic renal failure
. iron deficiency failure
13.

. platelet
. folic acid
. vitamin B12
. ferrous sulfate
. packed red cell
14.

. aspirin
. Vit. c
. amoxy
. Amitryptyline
.

15 -18
19.

.

.

20.

.
.
.
.

21.

. Ginkgo , Tanakan

. chitosan
. hydroxyl citric acid
. medium chain triglyceride oil
. conjugated linoleic acid
22.

.
. dosage form
.
. 13
23.

145 .
61 . (BMI)
. 26
. 27
. 28
. 29
. 30
24.

Phentermine

.
.
.
.
.
25.
phentermine

2
.

2
26.
phentermine
1.

2.

3.

4.
thermogenesis
27.
phentermine
28.

. conjugated linoleic acid

. chitosan
. hydroxyl citric acid
. Catechin
29.
dietary fiber
. chitosan
. evening primrose oil
. collagen
. conjugated linoleic acid
. Lecitin

tablet
37.5 mg

Tapioca starch, confectionness

sugar 8%
PVP in 50% ethanol , magnesium
stearate, colloidal silicon
dioxide,flavors and colors

30.

. Tapioca starch
. Confectionness sugar
. Sodium starch glycolate
. magnesium stearate
. colloidal silicon dioxide
4

 28

31.

.
. steroid
.
.
.
32.

.
systemic antibiotic

. antibiotic

33-38
39.
Isotretinoin
. Vitamin A

. Drug of choice

. serum
triglyceride
40. Isotretinoin 0.05%
.
.

.
.

5 57
stable angina 2
..
2542

Acute myocardial infraction (AMI)

Atenolol 50 mg PO OD
Ramipril 10 mg PO OD
Aspirin (ASA) 51 mg PO OD
Clopidogrel 75 mg PO OD
SL Isosorbide dinitrate (ISDN) 5 mg
Prn

6
TC
250 mg/dl
TG
245 mg/dl
41.

.
Simvastation 20 mg
flollow up
.
1

. Niacin
1gm BID follow up 6

.
Cholestyramine 4 gm BID
.
Gentibozil 600 mg BID
42.

(Rhabdo)
statin

. genfibrozil
.
propanolol
. Niacin
. enalapril
. cholertyramine
.
43.

. Atenolol
. Ramipril hypokalemia
. Cholestyramine

. Gentibrosil (blurred
vision)
. Isosorbide mononitrate

44.
Atenolol (
- block)
. heart rate
cardiac
output
. heart rate
cardiac output

. heart rate
cardiac
output
. rennin

. negative
feedback compensatory
outflow

45.
Sublingual isosorbide dinitrete

.

.

.
2

46.
isosorbide mononitrate 20 mg.

. 2
-
. 2 (3 )
. 2
-
. 2
. 2 (3 )
47.

. Atenolol
AMI
intrinsic
sympathomimetic activity
. Ramipril
heart
failure stroke
. Clopidogrel
Platelet glycoprotein I receptor
antagonist
. ASA
Clopidogrel
PT/ID
. ISDN Myocardial oxygen
demand HR BP
48.

Enalapril

. dissolution
.
. Active ingredient
. (limit)
Enalaprilat
. (limit)
piperazine diketone

49.

onset
duration
. Volatility
. route of administration
. metabolisum
. Structure (
oxide nitrogen
. alcohol
50. Angiotensin-converting
enzyme (ACE) inhibitor
pH

. Soft elastic capsule

. Enteric coating tublet
. Plastic natrices tablet
. Gastric floating tublet
. Methods unit tablet
6
20

5
51.

. Sinusitis
. Allergic rhinitis
. Cystitis
. Common cold
. Bronchitis
52.
4

Pseudoephredrine 60

.
2
.

.
53.

ephedrine
ephedrine

Pseudoephedrine

. 1,2
. 1,3
. 2,3
.
2,4
. 3,4
54.
ephedrine 0.5 1 drop bid

. 1
1

. 1
2
-
.
1 2
-
.
2 1
2 -
55.

.
hypertension
.
hyperglycemia
.
rebound congestion
.
insomnia
56.

. Preservative
. Coloring agent
. Buffering agent
. Antioxidant
. Toxicity adjusting agent
57.
ephedrine 0.5%
ephedrine 1.0%

1 . ephedrine 1.0% 2.5 ml

ml 2.5 ml
. ephedrine 1.0% 2.5 ml
NSS 5 ml

. ephedrine 1.0% 2.5 ml

acetate buffer 2.5
ml
. ephedrine 1.0% 2.5 ml
5 ml
. ephedrine 1.0% 2.5 ml
NSS 5 ml
58.


(. 1)
.
60 ml
.
120 ml
. Cofeed (Diphenhydramine
and ammonium chloride
. Terco-D (Dextromethrophan
and terpin hydrate)
. Godlpect (Codeine phosphate
and glyceryl guaicolate
59.

.
.
.
.
.
60.

.
.
.
.
.
7

30
2


2-3

2-3

61.

.

.
Aluminium
hydroxide
.

Magnesium
. 1
.

.
62.

.
..............
.
10
. -
20
. Cimetidine 200 mg
10
. 100

.63.

64.
(rheology)
.

65.

(Sedimentation rate)

.
.

.
methylcellulose
.
(Surfactant)

 Aluminum
hydroxide gel USP 26
Aluminum hydroxide
HCl

0.05 M disodium
ethylendiamine
(diNaEDTA)
5
Alcohol
dithis.. TS
0.05 M Zn SO4

66.

. redox direct titration

. acid-base back titration
. Precipitation back
titration
. Complexation back
titration
. Diazotization direct
titration
67.
68.

H2-blocker

.
8-12 wk.
.
duodenal ulcer gastric
ulcer
.
H. pytori
.

. prototype

69.

. Lupeol
. Curcumin
. Stignasterol
. andrographolide
. hydroxyanthracens
70.

.
.
.
.
.

8
29

1-2
3-4

71.

. T
. C
. Migraine
. T
. M

72.

. Methylergotamine
. Sunatriptane
. Amitriptyhline
. Naproxen
. Verapamil

ergotamine Caffeine
100 mg .
73.

. 1-2

.
30
.

. 6

74. Ergothamine

. Alkaloids
. Flavonoids
. Phenolics
. Tannins
. Terpenoids
75.

ergotamine

erythomycin

. Absorption
.
. Distribution
.
. Biotransformation

76.

ergotamine
. HPLC
. Ultra-Violet spectophotometry
. Potentiometry
. fluorometry
. Polamography
77.

. 2-3
/
.
. 12 .

55
.

78.

. Indomethacin
. Ergotamine
. Sumatriptan
. Propranolol
. Verapamil
79.

. 6

. 6

.
80.

. Amitriptyline
. Fluoxetine
. Propranolol
. Ketotifen
9
58 BMI = 28 kg/m2

(1) glibenclamide tablet (5) 1x2

AC
(2) metformin tablet (500) 1x3
AC
(3) Isoserbide mononitrate
tablet (20) 1x2 AC
(4) Aspirin tablet (300) 1x1 PC
81.

DM
.
.
.
.
.
82.

. glibenclamide
30

. aspirin

glibenclamide weight gain

.
metforin .
. alcohol
glibenclamine
83.
Metformin
glaucoma
Metformin
. glucoside
. rosiglitazone
. Chlorpropamide
84.

glibenclamide
. glucagon
. Insulin

. Insulin
. somatostatin
85.
Glibenstermine

. desensitization of sulfonylureas
receptor
. up-regulation of sulfonylureas
receptor
. down-regulation of
sulfonylureas receptor
. hyperinsulinemia
. increase insulin sensitivity
86.

.
aspirin
.
metformin
.
isosorbide mononitrate
.
glibenclamide
.

87. 10

uniformity
125
mg. S (Sample standard
deviation) RSD (relative
standard deviation)

. 2%
. 3%
. 4%
. 5%
. 6%
88. aspirin

. faking
. paling
. picking
. mottling
. capping
89.
. .

.
.
.
.

90.
glibenclamide

. polarized
.
HPLC-UV detection
.

10

Ethinyl estradiol 30 g
+ Levonorgestrel 0.15 mg

5
18.00 .

91.

. Lynestrenol
. Levonorgestrel
. Ethinyl estradiol +
Levonorgestrel
. Ethinyl estradiol + Desogestrol
. Ethinyl estradiol + Gestodene
92.

3
2
30 + 2

. Ethinyl estradiol 2.5 mg

2 3
. Levonorgestrel 0.75 mg 2
12 .
. Ethinyl estradiol
50 g + Levonorgestrel 0.25
mg2 12
.
93.
Levonorgestrel 17

.
.
.

Levonorgestrel 0.75 mg
20

HPLC Levonorgestrel
0.15 mcg/ml

1
2
3
ava s
rag d
e
stan 125 124 124 124 5
dar 000 000 500 500
d
sam 128 128 127 128 5
ple 000 500 500 00
94. Labeled amount
Levonorgestrel
. 98.8
. 99.8
. 100.8
. 101.8
. 102.8
95.

Levonorgestrel
. Identification
IR spectorphotometry
. Specific rotation
. Related substance
. UV analysis
. Loss on drying
96.
dose

. wet granulation
. dry granulation
. direct compression
. wet dry
granulation
. wet granulation
direct compression
97. Ethinyl estradiol

.
rifampin
.
corticosteroid
.
barbiturate
. phenyltoin

. aspirin

98. Ethinyl
estradiol + Levonorgestrel
. Ethinyl estradiol
estrogen
. Levonorgestrel
progestins
. Ethinyl estradiol
0.03 mg + Levonorgestrel 0.15
mg
biphasic combination 2

. Levonorgestrel

 Ethinyl
estradiol
. Levonorgestrel isomer
Norgestrel
99.
2
- Lynestrenol
Norethindrone
. Lynestrenol
estrogen
. Norethindrone
progestins
. Norethindrone
androgenic effect

Testosterone
. Lynestrenol androgenic
effect Norethindrone
. C=CH
2
oxidation OH
ketone
100. ... .. 2510

1.

1.

2.

3.
over the
counter
4.

11
27

2-3

paracetamol Ibuprofen 1.
20
2.

Paracet 1-2
4-6
Ibuprofen 1
3
101.
Primary dysmenorrhea
1.

27
2.

3.
.
4. 2-3

5.
paracet Ibuprofen
102.

. Ibuprofen

.
Ibuprofen
.

Ibuprofen
103. Ibuprofen

1.Serotonin
2.
Prostaglandin
3.Cycloxygenase
4.Leukotriene
5.thromboxane
104.
Ibuprofen 1 .

mefenamic acid
hyoscine-n-butylbomide

3. estradiol+ levonorgertrel
4. orphenadine
5. tolperisone
105.

1. aspirine
2. colcicine
3. naproxen
4. celecoxib
5. mefenamic acid
106. major
metabolite paracetamol

1.
2.
3.
4.
5.

107.

108.
Ibuprofen

1.
2
2.

3.

4.

109.
Paracet

1. punch
(deep concave punch )

2. die

3.
4. hygroscopic

5.

110. Ibuprofen

1.
2.
3.
4.
5.
12
8 ..

1
para syrup amoxicillin
dry powder 3
..
..

111.

1.
2.
3.

1.
2.
3.
4.
5.

4.

5.

..

..

112. ..
/

113.
..

1.

2.

..


..
.. 9

..
9
DTP MMR
1 ..

114.

1.

2.

3.
..
4.

5.

115. DTP MMR Vaccine

1. DTP vaccine
MMR vaccine

2. DTP vaccine

MMR vaccine

/
3. DTP vaccine inactivated
vaccine MMR liveattenuated vaccine
4. DTP vaccine toxoid
MMR vaccine
subunit vaccine
5. DTP vaccine subunit
vaccine MMR vaccine
toxoid

1.
2.
3.
4.
5.

1.
2.
3.
4.
5.

1.
2.
3.
4.
5.

116.
117.

live-attenuated vaccine

118.

1.
2.
3.

4.
5.
119. .. 4

.. 1.
.. 2.

3.
Chlorphenimine maleate tablet 4.
Hydroxyzine HCI tablet
5.
Neomycin/bacitracin ointment
Calamine lotion
Prednisolone cream
1.
120. 2.

Cost Minimization Analysis
Cost Effectiveness Analysis
Cost benefit Analysis
Cost Utility Analysis
Cost outcome Description

13
22 75 kg. 155
cm

Diclofenac gel

121.

glucosamine sulfate
hydroxychloroquine
aruanofin
Prednisolone
methotrexate
122.

3.

4.

5. codeine para

123.
diclofinac emulsion gel
1. carbopol
2.
preservative

3.

1.
2.
3.
4.
5.

freeze- cycle
4. emulsion gel

cream

5. emulfying
agent
124.

diclofinac emulsion
gel

125.
126.
1.

opioid analgesic
NSAIDs
2. opioid analgesic

3. NSAIDs

4.
opioid analgesic

5. cox-2

cox-1
127.
cox-2 selective
inhibitor
cox-2 selective inhibitor
1.
Cox-2 inhibitor Carboxyl

group
enzyme cox-2
2. cox-2 inhibitor

cox-2
3. cox-2 inhibitor
cox-2/cox-1 Selective
ratio
4. cox-2 inhibitor

sulfonamide
5. cox-2 inhibitor
Cox-2

cox-1
128. Diclofenac pKa = 4.5
(pH=1) .

1000/1
100/1
1/1
1/1000
1/100
129.


Diclofenac injection 75 mg/3 ml
Dexanethasone injection
Methadone tablet 10 mg
Prednisolone tab 5 mg
Rofecoxib tab 25 mg
130.

... 2510
1. Diclofenac tab 25 mg

2
2. Piroxicam cap 10 mg

3. Tolperisone 50
mg Diclofenac 25 mg

 1

4. Piroxicim 20mg

3
5. Rofecoxib 25 mg

1.

2.
14 3.
4.
45.

131.

1.
132.
2.
3.

4.
1.

2. 1.
steroid 2.
3. 3.

4.
4. 5.
Atropine

5.
(
)

133.
aqueos humer

1.
Timolol
. Pilocarpine
. Mannitol
. Thiazide
. Carbachol
134.

0.1% Diclofinac ED.

0.1% Fluorometholone ED
0.1% Dexamethasone ED
0.5% Atropine ED
0.05% Naphazoline ED
135. 0.5 % Atropine ED

7% Atropine
sulfate solution 0.9 %
NaCl
Atropine sulfate 0.5
g
NaCl
8.3 g
H2O
100 ml
Hypotonic solution
Hypertonic solution
Isotonic solution
Atropine sulfate
136.

Solution
Suspension
Ointment
Cream
Ocular insert
137.

1.

170 C 2 .
2.

3.

1.
2.
3.
4.
5.
1.
2.
3.
4.
5.

sterile membrane
4. LAL test
5. E.coli
10 cfc/ml
138.
139.

24 .
5
7
1
3
140.

Diclofenac ED
Chloramphenicol eye ointment
Timolol ED
Dexamethazone ED
Tetracycline eye ointment\
15

triamcinolone 0. %

% by weight
Triamcinolone acetonide
0.1
Lanolin ( HLB for o/w)
1.0
Stearic acid ( HLB for o/w)
2.0
1.
Propylene glycol
2.
8.0
3.
Liquid paraffin ( HLB for o/w)
4.
5.0
5.
Tween 80 ( HLB for o/w)
2.5

141.

1.Breaking
2.Cracking
3.Caping
4.Phase inversion
5.
Phase seperation
142.

1.
2.

3.

4.
(emulsifier)
5.

143. required HLB

o/w emulsion
stearic acid liquid
paraffin

1.9.5
2.10.75
3. 11.04
4.12.13
5.14.0
144.

o/w
Tween 80 : Span 80 = 8.43 : 2.87
Tween 80 : Span 80 = 2.87 : 8.43
Tween 80 : Span 80 = 15.0 : 3.7
Tween 80 : Span 80 = 3.7 : 15.0
Tween 80 : Span 80 = 1.5 : 2.5
145.

o/w

.
.
.
.
.

1.

( emulsifier
system) HLB
2.

( emulsifier
system) HLB
3.

( emulsifier
system) HLB
4.

( emulsifier
system) HLB
5.

( emulsifier
system) HLB
146. steroid

A. Hydrocortisone cream
2.5%
B. Clobatasol ointment
1.
0.05 %
2.
C. Triamcinolone 0.1%
D. Betametasone cream 3.
4.
B>D>C>A
5.
D>A>C>B
A>D>B>C
C>D>A>B
D>B>C>A
147.
glucocorticoids
.....
conjugated 3- ketone (b)11-OH
group (c)17 B ketol side
chain
acetonide 16
17

triamcinolone acetonide
1.
steroid
2. receptor
van der waal force
3.
lipophilicity
4.
hydrophiliciy
5. sodium retention

148.
triamcinolone acetonide
HPLC internal
standard fluoxymesterone
peak triamcinolone
peak fluoxymesterone
chromatogram
peak

flow rate
injection volume
column
guard column system
mobile
phase
149.

1.
triamcinolone lotion

2.
triamcinolone lotion

3.
triamcinolone
lotion

4.

1.
2.
3.
4.
5.

triamcinolone lotion

5.

150.
triamcinolone cream 0.1 %
15 g

49( 1)
1 Ishmic Hearth
Disease
HTN 5
HCTZ + Metoprolol

Lab BP 125/85
BUN Scr
1.
Metoprolol
-
heart attack
2. Metoprolol
5
3.
heart attack
- NTG
4. NTG
-

5.
NTG
1. ASSAY
2. Disolution
3. Dissintigration

4. Uniformity
6.

2 Asthma

Salbutamol MDI
PRN

1.

- GINA (
)
2.

1.
2.
3.
4.
5.
3. 2

- steroid
4.

- long acting Beta2 agonist

(,
)
5.

- Oral thrush
6. Prednisolone

- special control
7.

- spacer
()
8.
MDI DPI (dry powder
inhaler)

- Turbuhaler

9. Evohaler

3 Glaucoma
Betaxolol

.
1.

- Decrease aqueous humor

production
2.
- Atropine
3.

- Hyoscine
4.

5.

6.

7.
Compliance
8. .

9.

1.
2.
3.
4.
5.
4 Otitis Media

6
+

1.
- Strep pneumo.
2.
First choice
- Amoxycillin
3. Erythromycin
4.

Purified water
5. Preservative

- Paraben
6.

pseudoephedrine
7. Pseudoephedine

- P2
8.
- ..
9.
pseudoephedrine

10. 3

% LA
-

5 Anxiety /
Depression

1. -

2
1 .
2. Zolpidem

3.

Amitriptyline
4.
- Sertaline
5.

6. fluoxetine

-
7.
6 Parkisonism


?
levodopa/Carbidopa
Ibuprofen 400 mg
MTV
1.
Levodopa/Carbidopa
2.
On Off
3.

4.
Psychosis

MTV
5.
SAR
7 Oral
Contraceptives

1. Phyto
Estrogen
2. 3
3. EE

4. Progestogen

5.

-

6.

8 Primary
dysmennrhea +
+
5
1.

2.

3.

4.
Displcement Value = 2
1 20

5.

6.

9 Cysitis

1.

2.

3. Norfloxacin

4. 1 gr / 2 flz
-
5.

10 Gout

20 Lab

gout
1.

1.
2.
3.
4.
5.
2. gout attack
- Allopurinol
3.

- Low dose aspirin

NSAIDs Para
4.

5.

1. Para inhibit COX

2. Colchicine


3.

1

6.

Colchicine
-
7. Colchicine

8. K
Shelf-life

- 0.104/K

11 Diabetes
Miletus


2
Type II
2 Insulin




1.
- hypoglycemia
2. - Glucose
3. Shift electron

Chlopropamide
Tolbutamide

4. Insulin
-
5. Insulin
Glucagon
6. NPH

7. Insulin

8. Sulfonylurea

9.

Sulfonylurea

- Glipizide
Glipizide!?
10. Glipizide

1. Sulfonylurea----

2. Sulfone
11.
Scr

12.

13. Thiazolidinedione
Type I
-

14. Thiazolididione

- Hepatotoxicity
15.

12 Peptic Ulcer

3-5

1. Antacid

- 7

2.

3.

-
4. Antacid

5. GU, DU

6.
7. H2 Block
-
8. Triple therapy
- 3

9.

- curcumin

10.

13 Hypersensitivity

1. Type
2. Hydroxyzine 10 mg 1 x 3
3.
-

4.

5.

6.

7.

14 Vitamin A
Deficiency

5-6

1.

2.

-

3.

-
4.

- Cholestyramine
5. Cod liver oil

-
6. Preservative
7.
-

8. % RDA

RDA -

15 Vaccine and
Biologics


1.

-

Immunoglobulin


Immunoglobulin
tetanus
2.

3.

4.

5.

6.

7.
8.
9.

Imunoglobulin

-
Active HMI
5
2

-


5
6

Dry freeze

Pka
Pka

pH .
-

49( 2)
1 Heart Failure

HF
HCTZ

1.

2. HCTZ
- Gout
3. Cross allergy
Sulfa
HCTZ

4.

5. HCTZ

6.
HCTZ
7.
25 mg 1
1

- 30
2
Hyperlipidemia
Lab


LDL
+ Lab 7-8

1.
- atorvastatin

2.

Prodrug
3. Statin

- hepatotoxic

Lab

aminotransferrase
4. Gemfibrozil
5. Guideline

6.
7.
- CUA
3 DM

4 Renal

Diclofenac

1.

2.
-
3. Diclofenac

Lab
4. Diclofenac
5.

6.
7. -
8. -
-

5 HRT

1.

2.
vasomotor symptom
3.
EE
6 Osteoartritis


Glucosamine
40 40

1.
2.
OA
- ---,
,
3. /
OA
4. Glucosamine

5. Glucosamine

6. Calcium carbonate xx
mg / tab
calcium yyy mg
7.
Calcium
8. specific cox
2
7 Opportunistic
Infections

hiv +ve , CD4 cout 154

1. -
2.
- pessaries
3. PEG
4. Prophylaxis OIs

5.

6. CI 1

significant

8
.

1.
2. - ketoconazole
3. - 200 mg OD
4. Ketoconazole

-
5.
5

6. Ketoconazole

- CMA
7. pKa pH %

9
+ Lab +
+BSA
1. BSA
2. BSA
10 Pregnancy

1. Isotretinoin cat - X
2. teratogenic
3. Insulin

4.

5.

11 Allergy



1. Mediator
2.

3.
- CPM
4.

- 4
Low
5.
3

6.
7.
Cetyl acohol

12 Migraine
1.
Rofecoxib
2.
3. Ergotamine

4. Ergotamine

5.
13 Bacteria
Pharyngitis

Amoxy

1. -

2.

3. Rhinitis
medicament
4. 4
14 Bacteria
conjunctivitis
1.
2.
3.
meq/L
15 Diarrhea
2

1. Loperamide

2.
-
3. 5 anova
Article 1.

1. Thiethanolamine

2. Zeta Potential
3. Rx
X 0.5 ml E = 0.23, NaCl x ml
E = 0.1, q.s water 100 ml, Mft ad 30
ml X
4. NaCl 0.45 % 500 ml
meq
5.

6.
7. Theobroma oil

8.

9. 8
Assay .

1.

2. Science

Care
3.

4. Law

5. Econ 2 Epidermio
1 Research 1

6. medchem assay

50 ( 1)

Case 1 PU
1. cisapride

Case 2 vaccine
1. vac. .......
(BCG)
2. vac.
3. vac.
4. DTP
( 40
)
vac.

5. pt.
rabies vac.

choice

1. + betadine
2. + tetanus
3. + rabies
6.
vac.
Case 3 Migraine

1. (
case with or
without aura)
Case
pt.

metoclopramide + Ibuprofen
2. metoclopramide

3.

Case 4 Cystitis
Pt.

1.

2. pt.
Pt.
1

3.

4. pt.

5.
capsule
Case 5 Cancer
Pt. CHOP regimen
, . pt.

s/e

Case 6 renal
Pt. lab
(
urine)
1. (

prerenal, intrinsic
BUN/Scr >20:1
)
2. lab

hypokalemia , azotemia
3.
(poly / oligo /
normal/ anuria/.)

urine
Case 7 Bacterial conjunctivitis

1. isotonic

2. isotonic
hypo / hyper / isotonic

RBC
Case 8 Acne case

Case 9 Asthma
Case 10 Allergic rhinitis
Case 11 DM 2

Case 12 Ishemic heart disease

Case 13 Hyperlipidemia
()
Case 14 NSAIDs
Case 15 + HRT

50 ( 2)
Case 1
1.

choice

2.
KMnO4
3. pt.
( case)
4. DV
5.
Pt.

.


15 3

1. Pco

2.

3.
GI
4.

5. .

6.
2

Case 2 Hypothyroid
Lab
FT4 TSH

1.
2. /
(Myxo)
3. /
(Hashimoto.)
4. drug of choice
(levothyroxine)
5.
receptor
(I
,
D L
DL form)
6.
( T3
3 5
.......)
7. (
choice
therapy
TSH

 4-6
)
Case 3 Glaucoma
Pt.

1. pt.
2.
pt. ,

3. /
( )
4.
pt.
5. sterile
6.
...........
7. , pKa
atropine, atropine sulfate
(

pH
/
pKa )
Case 4 Depression

(
3-4 )
fluoxetine /
amitrip.
pt.

1.

2. (
)
3. SSRIs
..............
4.

( fluoxetine
MCQ & OSPE )
Case 5 Toxicology

Pt.
para.
1.

2. Antidote
3. func. Group
antidote
4.
(
effervescent )
5. Dead mixture
Case 6 DM + hyperlipidemia
1. pt. 2

2. NPH
intermediate
3. pt.
(

)
Case 7 HIV + TB

Pt.

1. Opportunistic infection

2.

CD4/ CD8
????
3.
metabolic ( PIs)
abacarvir
NRTIs
Case 8
1. Calamine
lotion


........
2.

1.

2.

3. Emulsifier

4.
flocculating

5.

Case 9 /
Case 10 Traveler diarrhea
(,
)
Case 11 HRT
Case 12 HTN
Case 13 RA + OA
Case 14 Sinusitis
Case 15 URI

Ospe

2551

( )

3-4

( 49
3),

HIV TB, OIs

( 50 2 7)

MCQ